F

or the past three years, various governments and patient advocacy groups have clamored for lower-cost hepatitis C medicines, given the high cure rate for these pricey new drugs. Now, a new study finds that upfront treatment with cheaper generic versions can offer a substantial payback.

Using a mathematical model for patients in India, researchers found that copycat versions costing around $300 would increase life expectancy by more than eight years and reduce lifetime health care costs by more than $1,300 per person. Moreover, treatment became cost effective in two years and upfront costs could be recovered inside of 10 years, according to the analysis published in PLOS ONE.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Facts that are … puzzling? “researchers found that copycat versions costing around $300…” And where will this $300 course of treatment come from vs. current $1,000/pill? Or does this imply $300/pill without saying it?

    • Hi Observer
      Thanks for the note. The researchers used a model and based it on the price for which generic versions of some drugs are available at that price.
      There is a link to the study, so you can read more.
      ed at pharmalot

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.